香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至二零二三年六月三十日止六個月 中期業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公佈本公司及其附屬公司（統稱「本集團」、「我們」）截至 二零二三年六月三十日止六個月（「報告期」）的未經審計綜合中期業績，連同截至 二零二二年六月三十日止六個月（「同期」）之比較數字。除非在本公告內另有界 定，否則本公告內詞彙具有招股章程所界定的相同涵義。 本公告所載若干金額及百分比數字已作四捨五入調整，或約整至小數點後一位或 兩位。任何表格、圖表或其他地方所列總數與數額總和之間如有任何差異，皆因 約整所致。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821) 2023年第一季度報告 本公告乃由凱萊英醫藥集團（天津）股份有限公司（「公司」或「本公司」，連同其 附屬公司「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09條及第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部項下的 內幕消息條文（定義見上市規則）而作出。 以下為本公司的2023年第一季度報告。本季度報告所載之財務數據根據中國企業 會計準則編製。本2023年第一季度報告未經審計。 本公司2023年第一季度報告以中、英文雙語編製。如兩個版本有任何不相符之 處，應以中文版本為準。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 ...

Financial Performance - In 2022, Asymchem Laboratories achieved revenue of approximately RMB 10,230,186 thousand, an increase of 120.9% compared to RMB 4,632,121 thousand in the previous year[8]. - Gross profit for the year was approximately RMB 4,832,588 thousand, up 135.8% from RMB 2,049,725 thousand in 2021[8]. - Net profit attributable to shareholders was approximately RMB 3,301,635 thousand, representing a 208.8% increase from RMB 1,069,274 thousand in the prior year[8]. - Adjusted net profit attributable to shareholders, excluding IFRS adjustments, was approximately RMB 2,998,806 thousand, a 167.0% increase from RMB 1,122,997 thousand in 2021[8]. - Revenue increased significantly from RMB 1,822,787 thousand in 2018 to RMB 10,230,186 thousand in 2022, representing a compound annual growth rate (CAGR) of approximately 46.5%[9]. - Net profit attributable to shareholders rose from RMB 428,202 thousand in 2018 to RMB 3,301,635 thousand in 2022, reflecting a CAGR of about 56.5%[9]. - Gross profit margin improved from 46.0% in 2018 to 47.2% in 2022, indicating enhanced operational efficiency[9]. - The total assets increased from RMB 3,188,076 thousand in 2018 to RMB 18,239,273 thousand in 2022, showcasing robust growth in the company's asset base[9]. - The company achieved total revenue of RMB 10.23 billion in 2022, representing a year-on-year growth of 120.9%[31]. - The small molecule CDMO business generated revenue of RMB 9.23 billion, up 118.1% year-on-year, while emerging services revenue reached RMB 993 million, growing by 150.3%[31]. - Revenue from overseas markets amounted to RMB 8.67 billion, reflecting a year-on-year increase of 117.2%, with the Americas growing by 112.7% and the Asia-Pacific region (excluding China) increasing by 169.9%[35]. - The company's net profit attributable to shareholders reached RMB 3.30 billion, a significant increase of 208.8%, with a net profit margin of 32.3%[36]. - The gross profit margin improved to 47.2%, up 3.0 percentage points from 2021, driven by economies of scale and high capacity utilization[36]. Business Growth and Strategy - The company reported a significant growth in emerging business revenue, reaching nearly RMB 1 billion in 2022, a year-on-year increase of about 150%[6]. - Asymchem's strategic planning continues to evolve, focusing on technology-driven growth and exploring new business models to enhance revenue contributions[7]. - The company aims to maintain its leading position in small molecule CDMO while injecting new growth engines through emerging business developments[7]. - The company has achieved over 33% application rate of continuous reaction technology and biocatalysis technology in late-stage clinical projects[15]. - The company has expanded its small molecule CDMO service capabilities to include new drug categories such as peptides, oligonucleotides, monoclonal antibodies (mAb), antibody-drug conjugates (ADC), and mRNA[20]. - The company has established a comprehensive biocatalysis technology platform with over 2,400 enzymes in its library, 40% of which are proprietary intellectual property[21]. - The company’s fermentation production capacity reaches 10,000L per week, providing high-quality production capabilities from milligrams to tons[21]. - The company has provided process development and production services to over 800 global clients since 2016, including several blockbuster drugs with sales exceeding $1 billion[23]. - The company has established strong partnerships with 15 of the top 20 global pharmaceutical companies, maintaining long-term collaborations with eight of them for over ten years[28]. - The company is expanding its CDMO capabilities into new business areas such as peptides, oligonucleotides, and biologics, enhancing its service offerings[25]. Research and Development - The company invested RMB 708.9 million in R&D, marking an 83.0% increase and accounting for 6.9% of total revenue[68]. - The company has a workforce of over 4,656 scientists and engineers, supporting its advanced R&D platform and driving technological innovation[26]. - The company has achieved a 100% pass rate in 35 official audits by major regulatory agencies since 2011, including FDA and NMPA[27]. - The company has developed a comprehensive operational system that meets the highest global industry standards in R&D, production, quality control, and project management[27]. - The company is committed to enhancing its strategic decision-making through expert advisory committees, including the BSA and BDSA, to drive technological advancement and market expansion[30]. Market Trends and Projections - The global pharmaceutical R&D investment is projected to grow from USD 243.7 billion in 2022 to USD 328.8 billion by 2026, with a CAGR of approximately 7.8%[10]. - The outsourcing ratio of pharmaceutical R&D investment in China is expected to rise from 42.6% in 2022 to 52.2% by 2026, indicating a growing trend in outsourcing services[11]. - The number of pharmaceutical R&D companies in China surged by 43.3% from 522 in 2021 to 792 in 2022, reflecting a shift towards innovation[12]. - The global CDMO market for pharmaceutical R&D services is anticipated to grow from RMB 131.2 billion in 2022 to RMB 336.8 billion by 2026, with a CAGR of approximately 26.6%[13]. Corporate Governance and Leadership - The board consists of nine members, including four executive directors, two non-executive directors, and three independent non-executive directors[115]. - The company has a strong leadership team with extensive experience in various sectors, enhancing its strategic direction and operational efficiency[116][117][118][119][120]. - The board's composition reflects a balance of executive and independent oversight, ensuring robust governance practices[115]. - The company emphasizes the importance of good corporate governance for enhancing management and protecting overall shareholder interests[200]. - The board believes that the company has complied with the relevant provisions of the corporate governance code during the reporting period, except for clause C.2.1[200]. Sustainability and Compliance - The company is committed to sustainable development by creating low-energy, low-emission, and high-efficiency operational models[15]. - The company emphasizes the importance of environmental policies and has implemented measures to reduce energy consumption and waste[146]. - The company is committed to compliance with environmental, social, and governance regulations, with details to be disclosed in future reports[146]. - The company has not identified any significant non-compliance issues with relevant laws and regulations[146]. Future Outlook - The company has outlined a positive future outlook, projecting a revenue growth of 10-15% for the upcoming fiscal year[123]. - The company aims to deepen relationships with large clients while actively expanding its presence in the European and Japanese markets, focusing on cost control and efficiency improvements in 2023[106]. - The company plans to enhance its small molecule CDMO business and accelerate the development of strategic emerging businesses, leveraging a robust operational management system[106]. - The company is committed to enhancing clinical research services, aiming to establish a strong industry reputation and increase the number of clinical research service orders[110].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或倚賴該 等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至2022年12月31日止年度之年度業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公布本公司及其附屬公司（統稱「本集團」、「我們」）截至 2022年12月31日止年度（「報告期」）的經審計綜合年度業績，連同截至2021年12 月31日止年度（「同期」）之比較數字。本集團於報告期間的綜合財務報表已由審核 委員會審閱及由本公司核數師安永會計師事務所審核。除非本公告另有界定，否 則本公告所用詞彙與本公司日期為2021年11月30日的招股章程（「招股章程」）所 界定者具有相同涵義。 本公告所載若干金額及百分比數字已作四捨五入調整，或約整至小數點後一位或 兩位 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或倚賴該 等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至2022年12月31日止年度之年度業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公布本公司及其附屬公司（統稱「本集團」、「我們」）截至 2022年12月31日止年度（「報告期」）的經審計綜合年度業績，連同截至2021年12 月31日止年度（「同期」）之比較數字。本集團於報告期間的綜合財務報表已由審核 委員會審閱及由本公司核數師安永會計師事務所審核。除非本公告另有界定，否 則本公告所用詞彙與本公司日期為2021年11月30日的招股章程（「招股章程」）所 界定者具有相同涵義。 本公告所載若干金額及百分比數字已作四捨五入調整，或約整至小數點後一位或 兩位 ...

Financial Performance - Revenue for the six months ended June 30, 2022, reached RMB 5,034,065 thousand, representing a 186.7% increase compared to RMB 1,755,569 thousand for the same period in 2021[14]. - Gross profit for the same period was RMB 2,363,225 thousand, up 200.9% from RMB 785,387 thousand year-over-year[14]. - Net profit attributable to shareholders for the six months ended June 30, 2022, was RMB 1,740,095 thousand, a significant increase of 305.3% from RMB 429,327 thousand in the prior year[14]. - The adjusted net profit attributable to shareholders, based on non-IFRS measures, was RMB 1,537,478 thousand, reflecting a 244.8% increase from RMB 445,943 thousand in the previous year[14]. - Basic earnings per share for the period was RMB 4.75, a 274.0% increase compared to RMB 1.27 for the same period in 2021[14]. - The gross margin improved to 46.9% from 44.7% year-over-year[14]. - The net profit margin attributable to shareholders increased to 34.6% from 24.5% in the prior year[14]. Market Position and Strategy - The company is the fifth largest innovative drug API CDMO globally and the largest commercial stage chemical drug CDMO in China, according to Frost & Sullivan's 2020 revenue statistics[21]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[13]. - Asymchem Laboratories continues to explore strategic partnerships and potential acquisitions to drive growth and innovation in the biopharmaceutical sector[13]. - Future outlook remains positive with expectations for continued revenue growth and improved profitability driven by increased demand for CDMO services[13]. - The company aims to expand its CDMO capabilities into new business areas, including large molecule CDMO, formulation, and clinical CRO services[24]. Operational Highlights - The company has established a research and production center for antibodies and ADC drugs in Shanghai, and a plasmid and mRNA business R&D base in Suzhou to meet the growing demand from domestic and international clients[25]. - The company has a production capacity of 10,000L/week for enzyme fermentation, with capabilities for high-quality production from milligram to ton scale[25]. - The company completed 34 commercial stage projects and 220 clinical stage projects during the reporting period, with 48 in clinical phase III[38]. - The company has developed over 2,400 enzymes, with 40% of them having proprietary IP, and has launched 15 enzyme reagent kits for rapid target enzyme screening[25]. - The company has established a synthetic biology technology R&D center since 2021, developing nearly 2,400 engineered enzymes and holding over 800 IPs across more than 20 categories[53]. Research and Development - R&D investment for the first half of 2022 reached RMB 263 million, a year-on-year increase of 60.67%, positioning the company among industry leaders[56]. - The newly created high-throughput screening and engineering modification technology platform aims to enhance the foundational capabilities in synthetic biology[59]. - The company is committed to continuous technological innovation and aims to develop internationally leading patented technologies for commercial production[126]. - The company is focusing on developing advanced drug delivery technologies to improve drug efficacy and reduce costs, addressing key industry challenges[59]. Financial Position and Cash Flow - The total equity attributable to shareholders was approximately RMB 14,586.17 million as of June 30, 2022, compared to RMB 6,287.10 million as of June 30, 2021[117]. - Cash and bank balances decreased by 7.5% from RMB 6,234.5 million as of December 31, 2021, to RMB 5,764.8 million as of June 30, 2022, primarily due to idle funds being used to purchase financial assets at fair value through profit or loss[106]. - Net cash flow from operating activities was RMB 631.78 million, an increase attributed to revenue growth, despite increased material ordering costs and timing differences in revenue recognition[116]. - Net cash flow used in investing activities was RMB 3,235.04 million, an increase of RMB 1,252.54 million, mainly due to capacity expansion, new technology investments, and the purchase of principal-protected short-term bank financial products[116]. Talent and Governance - The company has a workforce of 8,931 employees, with over 4,200 in R&D and analysis roles, and has recruited 110 senior talents in the first half of 2022[69]. - The management team has an average of 20 years of industry experience, emphasizing the company's strong leadership and commitment to talent development[78]. - The company is committed to enhancing its talent strategy and optimizing its organizational structure to improve operational efficiency and employee development[133]. - The company has adopted the corporate governance code and has complied with its principles throughout the reporting period, except for the separation of the roles of Chairman and CEO[177]. Risks and Challenges - The company has identified potential risks, including the risk of major innovative drugs being withdrawn from the market or recalled, and operational risks associated with clinical stage projects[134]. - The company has not recommended the payment of an interim dividend for the six months ended June 30, 2022[135].

Financial Performance - Asymchem Laboratories reported a revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 25%[4] - The company's revenue for the reporting period was approximately RMB 4.63 billion, an increase of 47.7% compared to RMB 3.14 billion in the same period of 2020[18] - Gross profit for the reporting period was approximately RMB 2.05 billion, up 41.0% from RMB 1.45 billion in 2020[18] - Net profit attributable to shareholders was approximately RMB 1.07 billion, representing a 48.6% increase from RMB 719.74 million in 2020[18] - The company's total revenue for the reporting period reached RMB 4.632 billion, representing a year-on-year growth of 47.67%, and a growth of 56.38% when excluding exchange rate effects[35] - The net profit attributable to shareholders was RMB 1.069 billion, reflecting a year-on-year increase of 48.47%[39] - Revenue increased by 47.7% from RMB 3,136.7 million in 2020 to RMB 4,632.1 million in 2021, driven by a 46.02% growth in small molecule CDMO business[70] - Commercialization revenue grew by 52.11% to RMB 2,511.3 million, accounting for 54.22% of total revenue[71] - Revenue from emerging services increased by 67.88% to RMB 397.0 million, representing 8.57% of total revenue[71] Market Expansion and Strategy - Asymchem is expanding its market presence in Europe and North America, with plans to establish new partnerships and collaborations[4] - The company plans to actively expand into new markets, particularly the US biotech market, to support future growth[17] - The company aims to enhance its comprehensive competitiveness by ensuring high-quality delivery of large orders and expanding its global market share, particularly in the small molecule CDMO business[112] - In 2022, the company plans to increase its small molecule production capacity by over 2,000m³, with new facilities in Dunhua, Tianjin, and the Yangtze River Delta region[118] - The company is focusing on accelerating the development of new drug categories and service types, including advancing small nucleic acid CDMO services and establishing a strong presence in clinical research services[114] Research and Development - The company is investing RMB 200 million in R&D for new product development, focusing on biologics and advanced drug delivery systems[4] - R&D investment reached 387 million RMB, a year-on-year increase of 49.64%, accounting for 8.37% of total revenue, positioning the company among the global industry leaders[57] - The company established four R&D technology platforms to address project development challenges and enhance innovation capabilities[57] - The company is increasing its investment in R&D to ensure a higher application ratio of new technologies, maintaining its technological edge in the industry[119] Operational Efficiency and Capacity - The company reported a significant increase in production capacity, with a 40% rise in output from its Tianjin facility[4] - The company has successfully expanded its CDMO capabilities to include new drug categories such as peptides, oligonucleotides, and mRNA[32] - The company optimized the synthesis process for an innovative anti-tumor drug, reducing the production cycle from 130 days to under 60 days, increasing yield by nearly 300%[46] - The company has implemented continuous reaction technology, achieving a production capacity of 1.3 tons per day for key raw materials, which would require 180m³ of batch capacity to produce the same scale[65] Sustainability and Corporate Responsibility - The company emphasized its commitment to sustainability, with plans to reduce carbon emissions by 30% by 2025[4] - The company has implemented environmental policies and measures to reduce energy consumption and waste, demonstrating its commitment to sustainability[157] Corporate Governance and Management - The board consists of nine members, including four executive directors, two non-executive directors, and three independent non-executive directors[126] - The company has a strong focus on operational and financial supervision, with key personnel responsible for these areas having extensive backgrounds in management and finance[135] - The management structure includes a mix of long-serving members and new appointees, fostering continuity and fresh perspectives[137] - The company emphasizes corporate governance and daily operations management, led by Xu Xiangke, who has extensive experience in corporate affairs[142] Financial Position and Investments - Total assets increased to approximately RMB 15.16 billion, while total liabilities rose to RMB 2.55 billion, resulting in a debt-to-asset ratio of 16.8%[22] - Cash and cash equivalents increased by 193.4% from RMB 2,124.6 million in 2020 to RMB 6,234.5 million in 2021, mainly due to funds raised from a global offering[93] - The company completed the issuance of H-shares, raising approximately HKD 6.85 billion, which will be used to strengthen global operations and enhance CDMO capabilities[68] Talent Management and Human Resources - The company has a workforce of 7,126 employees, with 3,381 in R&D and analysis roles, accounting for 47.45% of the total[66] - The company focuses on talent management and has established mechanisms for talent selection, evaluation, and incentives to enhance its human resources strategy[123] - The company introduced 49 senior talents during the reporting period, including 18 PhDs and 16 senior executives, to enhance its drug development ecosystem[66] Risks and Challenges - Potential risks include the risk of major innovative drugs being withdrawn from the market, operational risks in clinical projects, and lifecycle replacement risks of key innovative drugs[124] - The company has faced challenges such as regulatory scrutiny from international drug authorities and the potential loss of core technical personnel[124]